TG Therapeutics presents 7-year data for BRIUMVI showing sustained disease control in relapsing multiple sclerosis

TG Therapeutics has announced updated clinical data at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, including seven-year follow-up data from the ULTIMATE I & II trials for BRIUMVI (ublituximab). The data demonstrate sustained disease control, with approximately 88% of participants remaining free from confirmed disability progression after seven years of continuous treatment for relapsing multiple sclerosis. Additionally, a late-breaking oral presentation on Azer-cel in primary progressive multiple sclerosis is scheduled for October 23, 2026.